Table 1. Demographics of study populations.
| HCV | HBV | HCV/HBV, all | |||
| Untreated follow-up | All | Untreated follow-up | All | p value | |
| Male gender, n (%) | 246 (62) | 381 (64) | 61 (46) | 111 (47) | <0.001 |
| Age at first scan (years), median (IQR) | 45 (36–52) | 45 (36–52) | 34 (29–43) | 36 (29–47) | <0.001 |
| Injecting drug use (ever), n(%) | 248 (63) | 374 (63) | 1 (1) | 3 (1) | <0.001 |
| Self reporet alcohol overuse (ever), n(%) | 187 (47) | 248 (42) | 12 (9) | 20 (9) | <0.001 |
| Baseline liver stiffness, median(IQR) | 6.9 (5.6–10.5) | 6.9 (5.4–11.8) | 5.2 (4.2–7) | 5.2 (4.3–6.8) | <0.001 |
| Baseline liver stiffness ≥17 kPa, n (%) | 46 (12) | 94 (16) | 1 (1) | 7 (3) | <0.001 |
| Liver biopsy Metavir score* | |||||
| Fibrosis, median (IQR) | 1.5 (1–3) | 1.5 (1–3) | 1 (0.5–1) | 1 (0–1) | 0.041 |
| Activity, median (IQR) | 0.5 (0–2) | 1 (0–2) | 0 (0–1.5) | 0 (0–2) | 0.224 |
| Liver Biopsy with cirrhosis, n (%) | 29 (7) | 47 (8) | 0 (0) | 2 (1%) | <0.001 |
| Observed clical decompentsations, n (%) | 32 (8) | 61 (10) | 0 (0) | 4 (2) | <0.001 |
| Observed total deaths, n (%) | 27 (7) | 50 (8) | 0 (0) | 5 (2) | <0.001 |
| Liver related deaths, n (%)** | 5 (1) | 12 (2) | 0 (0) | 0 (0) | 0.030 |
| Sum of follow up in person years | 1133 | 2198 | 0 (0) | 744 | |
| Total, n (%) | 396 (100) | 597 (100) | 134 | 234 (100) | |
These data exclude 13 patients co-infected with HBV and HCV, and include 29 patients co-infected with HIV.
* Liver biopsy data for 68 patients with biopsy within one year of liver stiffness measurement.
**Excluding 1 hepatitis C patient with an unconfirmed liver-related cause of death.